Document Detail


Can we reduce the dosage of biologics in spondyloarthritis?
MedLine Citation:
PMID:  22940233     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
TNF blockers have revolutionized the management of spondyloarthritis (SpA). To date, four anti-TNFα agents (etanercept, infliximab, adalimumab, golimumab) have been approved for the management of ankylosing spondylitis (AS) and psoriatic arthritis (PsA). The first objective in the management of AS and PsA with TNF inhibitors is to reduce disease activity to clinical remission or low disease activity. After remission has been achieved, this state should be maintained as long as possible. However, the financial burden associated with the cost of anti-TNF agents as well as concerns about their long-term safety suggest reducing the dosage of the drug or discontinuing the therapy in the hopes of drug-free remission. The aim of this review is to examine what has, till now, been published on this topic in axial SpA, which includes AS and non-radiographic axial SpA (nr-axSpA), peripheral SpA and PsA. Discontinuation of therapy in axial SpA is not possible in the majority of patients, while on the contrary, reducing the dosage often is. In some patients with peripheral SpA and PsA it is also possible to discontinue therapy and to achieve drug-free remission.
Authors:
Ignazio Olivieri; Salvatore d'Angelo; Angela Padula; Pietro Leccese; Angelo Nigro; Carlo Palazzi
Related Documents :
23865413 - Immunomodulation in inflammatory neuropathies: rationale and safety.
24693873 - Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the...
8127253 - Clinical relevance of in vitro drug resistance testing in childhood acute lymphoblastic...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-8-23
Journal Detail:
Title:  Autoimmunity reviews     Volume:  -     ISSN:  1873-0183     ISO Abbreviation:  Autoimmun Rev     Publication Date:  2012 Aug 
Date Detail:
Created Date:  2012-9-3     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101128967     Medline TA:  Autoimmun Rev     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier B.V.
Affiliation:
Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza and Matera, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An immortalised astrocyte cell line maintains the in vivo phenotype of a primary porcine in vitro bl...
Next Document:  The relationship between geometric patterns of hydrogen bonds and periodic dinucleotides in nucleoso...